About Audentes Therapeutics
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BOLD
- Previous Close: $15.80
- 50 Day Moving Average: $16.33
- 200 Day Moving Average: $16.49
- 52-Week Range: $13.06 - $20.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.67
- P/E Growth: -1.52
- Market Cap: $349.77M
- Outstanding Shares: 21,725,000
- Return on Assets: -41.00%
Companies Related to Audentes Therapeutics:
- Debt-to-Equity Ratio: -0.03%
- Current Ratio: 12.35%
- Quick Ratio: 12.35%
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?
3 brokers have issued 1 year price targets for Audentes Therapeutics' shares. Their predictions range from $20.00 to $24.00. On average, they anticipate Audentes Therapeutics' share price to reach $22.00 in the next year.
When will Audentes Therapeutics announce their earnings?
Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 10th 2016.
Who owns Audentes Therapeutics stock?
Audentes Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (22.10%), Deerfield Management Co. (6.46%), Franklin Resources Inc. (1.69%), FMR LLC (1.61%), Eventide Asset Management LLC (1.04%) and Alyeska Investment Group L.P. (0.46%). Company insiders that own Audentes Therapeutics stock include James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc.
Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?
Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..
Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?
Audentes Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp and Perceptive Advisors LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc.
How do I buy Audentes Therapeutics stock?
Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Audentes Therapeutics stock cost?
One share of Audentes Therapeutics stock can currently be purchased for approximately $16.16.